Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 3.19 EUR -0.93%
Market Cap: 254.8m EUR

Oryzon Genomics SA
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oryzon Genomics SA
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Oryzon Genomics SA
MAD:ORY
Free Cash Flow
-€13.4m
CAGR 3-Years
5%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Grifols SA
MAD:GRF
Free Cash Flow
€858.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Free Cash Flow
€16.2m
CAGR 3-Years
-23%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Free Cash Flow
€108.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Oryzon Genomics SA
Glance View

Market Cap
247.3m EUR
Industry
Biotechnology

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

ORY Intrinsic Value
1.15 EUR
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Oryzon Genomics SA's Free Cash Flow?
Free Cash Flow
-13.4m EUR

Based on the financial report for Dec 31, 2024, Oryzon Genomics SA's Free Cash Flow amounts to -13.4m EUR.

What is Oryzon Genomics SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
0%

Over the last year, the Free Cash Flow growth was 11%. The average annual Free Cash Flow growth rates for Oryzon Genomics SA have been 5% over the past three years .

Back to Top